Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. They help your body fight infections. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the ...

FL, follicular lymphoma; NLCS, National LymphoCare Study; R-CVP, rituximab with cyclophosphamide, vincristine, and prednisone; R-Flu, rituximab with fludarabine. We identified an independent ...

Throughout the follicular phase, a single "dominant follicle" develops faster than the rest. This follicle (a fluid-filled sac in your ovary) then releases more estrogen into the body in ...

In this episode, Vi-Anne Antrum, Senior Vice President & Chief Nursing Officer at Cone Health, discusses the organization’s transformative journey, including a $150 million investment in health ...

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...

Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase 1 study evaluating BAFF-R targeting CAR T cells (PMB-CT01 ...

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable. There have been a number of advancements in the treatment of follicular lymphoma in 2024.

For the follicular lymphoma trial, patients receiving loncastuximab and rituximab had a 67% complete response rate, meaning their cancer could no longer be detected by imaging, and an overall ...

The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy. This now makes epcoritamab-bysp the first and ...

With a new FDA nod, BeiGene has filled the follicular lymphoma approval gap for BTK inhibitors. Thursday, the FDA doled out an accelerated approval for BeiGene’s Brukinsa to be used alongside ...

T follicular helper cells (Tfh cells) are a specialized subgroup within the so-called CD4 + T helper cells in the immune system. Their main task is to assist the B cells in the immune defense.